title: In-vitro susceptibility of 1982 respiratory tract pathogens and 1921 urinary tract pathogens against 19 antimicrobial agents: a Canadian multicentre study. Canadian Antimicrobial Study Group.
abstract: A total of 3903 pathogens from 48 Canadian medical centres were tested against 19 antimicrobial agents. Five agents showed activity against > or = 90% of all 1982 respiratory tract pathogens tested (ciprofloxacin, 90%; cefoperazone, 91%; ticarcillin/clavulanate, 92%; ceftazidime and imipenem, 93% each). Nine agents had > or = 90% activity against Enterobacteriaceae from respiratory tract infection (cefotaxime and ticarcillin/clavulanate, 90% each; aztreonam, ceftizoxime and ceftriaxone, 91% each; ceftazidime, 93%; ciprofloxacin, 97%; imipenem and netilmicin, 98% each). Similarly, five agents had activity against > or = 90% of all 1921 urinary tract pathogens tested (ciprofloxacin and ticarcillin/clavulanate, 90% each; cefoperazone and netilmicin, 91% each; imipenem, 99%). Nine agents had > or = 95% activity against Enterobacteriaceae from urinary tract infection (ciprofloxacin, 95%; cefotetan, 97%; aztreonam, cefotaxime, ceftazidime, ceftizoxime, ceftriaxone and netilmicin, 98% each; imipenem, 99%). Seventeen agents had activity against > or = 95% of Staphylococcus aureus strains. Susceptibility of Pseudomonas aeruginosa isolates ranged from 2% to 91%.
authors.affiliation: Division of Clinical Microbiology, Saskatoon District Health and St Paul's Hospital (Grey Nuns) and the University of Saskatchewan, Saskatoon, Canada. blondeauj@sdh.sk.ca
authors.forename: J M
authors.initials: JM
authors.lastname: Blondeau
authors.forename: Y
authors.initials: Y
authors.lastname: Yaschuk
authors.forename: M
authors.initials: M
authors.lastname: Suter
authors.forename: D
authors.initials: D
authors.lastname: Vaughan
mesh_terms: D000150:Acinetobacter / Q000187:drug effects; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002438:Cefoperazone / Q000494:pharmacology; D002442:Ceftazidime / Q000494:pharmacology; D002939:Ciprofloxacin / Q000494:pharmacology; D002969:Clavulanic Acids / Q000494:pharmacology; D004755:Enterobacteriaceae / Q000187:drug effects*; D004756:Enterobacteriaceae Infections / Q000382:microbiology*; D016983:Enterococcus / Q000187:drug effects; D006190:Haemophilus / Q000187:drug effects; D006801:Humans; D015378:Imipenem / Q000494:pharmacology; D020128:Inhibitory Concentration 50; D008826:Microbial Sensitivity Tests; D009016:Moraxella / Q000187:drug effects; D011549:Pseudomonas / Q000187:drug effects; D012141:Respiratory Tract Infections / Q000382:microbiology*; D013210:Staphylococcus / Q000187:drug effects; D013291:Streptococcus / Q000187:drug effects; D013982:Ticarcillin / Q000494:pharmacology; D014552:Urinary Tract Infections / Q000382:microbiology*
chemical_list: D000900:Anti-Bacterial Agents; D002969:Clavulanic Acids; D002939:Ciprofloxacin; D015378:Imipenem; D002438:Cefoperazone; C043215:ticarcillin-clavulanic acid; D002442:Ceftazidime; D013982:Ticarcillin